no more compounding glp 1 drugs GLP-1 from the Gray Market Decoding GLP-1 Weight Loss Medications

Cent Eur J Urol 2013

Introduction Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes (T2DM), with a relevant impact on the economic costs for health care systems and on the quality of life for many patients ( Among the novel therapies, great interest has been aroused by sodiumglucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), that have changed the management of diabetic patients

O., Pickholz, M., Remko, M., Saviano, M., Skwarczynski, M., Tang, Y., Wolf, W

BMJ (Clinical research ed) 2008;336:9246

The medical records did not show how severe the patients hair loss was, how long it lasted, or whether their hair eventually grew back